PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating.
PTC Therapeutics, Inc. (PTCT)
Last ptc therapeutics, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ptcbio.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
PTCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTCT alerts
High impacting PTC Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTCT
News
- InnovationRx: Trump Picks RFK, Jr. And Dr. Oz For Key Healthcare Roles [Forbes]Forbes
- PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at JPMorgan Chase & Co. from $51.00 to $62.00. They now have an "overweight" rating on the stock.MarketBeat
- PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Child Thriving After Becoming World's Youngest to Receive Gene Therapy for AADC Deficiency [Yahoo! Finance]Yahoo! Finance
- FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain [Yahoo! Finance]Yahoo! Finance
PTCT
Earnings
- 11/7/24 - Beat
PTCT
Sec Filings
- 11/14/24 - Form SC
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- PTCT's page on the SEC website